Stockholders' Deficit (Tables)

9 Months Ended

Sep. 30, 2021

Equity [Abstract]

Schedule of Shares Reserved for Future Issuance

The Company has reserved shares of common stock for future issuances as follows:

	September, 30		December, 31
	2021		2020
Series A redeemable convertible preferred stock outstanding		450,692		450,692
Series B redeemable convertible preferred stock outstanding		675,397		675,397
Series C redeemable convertible preferred stock outstanding		2,223,888		2,223,888
Series D redeemable convertible preferred stock outstanding		9,047,861		9,047,861
Warrants to purchase Series D redeemable convertible preferred stock		77,842		77,842
Convertible notes*		—		—
Common stock options issued and outstanding		2,170,894		2,466,594
Common stock available for future grants		59,187		67,010

* At September 30, 2021 and December 31, 2020, the conversion of the convertible notes into redeemable convertible preferred stock was dependent on the outstanding loan balance including accrued interest and the conversion stock per share price at the date of qualified equity financing, non-qualified equity financing, or a change of control event. These factors were not estimable and the number of redeemable convertible preferred stock was not determinable. There were no conversions of convertible notes to preferred stock for the nine month period ended September 30, 2021 and twelve month period ended December 31, 2020.

Schedule of Stock Option Activity

A summary of stock option activity is set forth below (in thousands, except share and per share data):

	Number of Shares Available for Grant			Number of Shares Underlying Outstanding Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding, January 1, 2021		67,010			2,466,594		$	0.61		5.21		—
Options authorized		1,653,955			—
Options granted		(1,784,086	)		1,784,086		$	11.25
Options exercised		—			(1,957,478	)	$	0.61
Options forfeited or cancelled		122,308			(122,308	)	$	1.48
Outstanding, September 30, 2021		59,187			2,170,894		$	9.31		8.86	$	8,283
Shares exercisable September 30, 2021					1,451,709		$	9.28		8.57	$	5,579
Vested and expected to vest, September 30, 2021					2,170,894		$	9.31		8.86	$	8,283

Summary of Stock-Based Compensation Expense

Total stock-based compensation expense recognized was as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Cost of goods sold	$	66	$	46	$	236	$	116
Sales and marketing		406		49		1,701		256
Research and development		8		1		127		7
General and administrative		595		109		3,620		375
Total	$	1,075	$	205	$	5,684	$	754

Schedule of Fair Value of Stock Options Estimated Using Weighted-Average Assumptions

The fair value of stock options was estimated using the following weighted-average assumptions:

	Nine Months Ended September 30,
	2021	2020
Expected volatility	72.9%-75.9%	61.6% - 75.2%
Risk-free interest rate	0.6%-1.1%	0.3%-0.7%
Dividend yield	0%	0%
Expected term	5-6.1 years	5-6.1 years